March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
Researchers highlight evidence-based lifestyle and pharmacologic strategies, including glycemic excursion minimization and tirzepatide, for early glycemic control in adults with type 2 diabetes.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
Only 5% of new drug approvals included human lactation data, according to researchers calling for improved lactation pharmacokinetics research for breastfeeding women.
At 12 months, women on hormone therapy achieved 16% total body weight loss with semaglutide, compared to 12% in those not using hormone therapy, researchers reported.